The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance. A new analysis using CRISPR screens has revealed insights that ...

Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...

Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...

DelveInsight's “PARP inhibitor Pipeline Insights 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP ...

Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the FDA- and EMA-approved poly ...

A phase 2 trial will analyze the novel drug ART4215 with Talzenna, a PARP inhibitor, for patients with BRCA-deficient breast cancer. A phase 2 expansion study is now underway, examining the novel drug ...

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

Image: Proliferating cells in a tumour organoid of triple-negative breast cancer. Credit: Dr Rebecca Marlow, The Institute of Cancer Research, London. Researchers at The Institute of Cancer Research, ...

A fast-growing body of research, both in vitro and in vivo, is converging to demonstrate the multiple inhibitory effects of Tumor Treating Fields on cancer growth The review article summarizes the ...